Minerva Neurosciences, Inc. (NERV)

Name: Minerva Neurosciences, Inc. (NERV) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001598646 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated MA
Fiscal year ends Dec 31

Partial revenue. In this company's filings, reported revenue for the year ended 2024-12-31 is zero or negative beside a profit. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-08-12

Headquarters locality: Waltham · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-8, first reflected in a filing dated 2022-08-09. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	n/a	n/a	$0	$0	$0	$0	$0	$0	$0	n/a	n/a
R&D Expense	$15.54M	$5.76M	$11.90M	$12.71M	$14.65M	$32.04M	$22.04M	$58.12M	$34.89M	$30.26M	$20.44M
Operating Income	-$35.14M	-$15.10M	-$21.85M	-$23.12M	-$25.23M	-$45.37M	$1.85M	-$75.87M	-$51.73M	-$41.17M	-$30.19M
Depreciation & Amortization	n/a	$5.4K	$5.4K	$5.4K	n/a	n/a	n/a	n/a	n/a	n/a	n/a
EBITDA	n/a	-$15.10M	-$21.84M	-$23.11M	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Net Income	-$394.35M	-$293.42M	$1.44M	-$30.01M	-$32.11M	-$49.91M	$1.94M	-$72.18M	-$50.17M	-$31.52M	-$31.05M
EPS (Diluted)	n/a	-$34.67	$0.19	-$4.61	-$6.01	-$9.35	$0.05	-$1.85	n/a	n/a	n/a
Total Assets	$95.09M	$97.97M	$37.14M	$56.90M	$55.09M	$77.12M	$57.63M	$77.50M	$139.14M	$183.70M	$132.94M
Total Liabilities	$296.65M	$233.76M	$62.84M	$85.36M	$75.11M	$69.15M	$4.96M	$49.72M	$48.87M	$52.10M	$26.96M
Shareholders' Equity	-$213.30M	-$140.75M	-$25.69M	-$28.46M	-$20.02M	$7.98M	$52.66M	$27.78M	$90.26M	$131.60M	$105.98M
Cash & Equivalents	$24.65M	$82.30M	$21.36M	$40.91M	$36.09M	$60.76M	$25.36M	$21.41M	$50.23M	$26.05M	$82.98M
Operating Cash Flow	-$26.17M	-$13.51M	-$19.55M	-$14.78M	-$24.65M	-$24.60M	-$33.82M	-$43.43M	-$41.94M	$3.09M	-$25.69M
Capital Expenditures	n/a	n/a	n/a	n/a	$16.3K	n/a	n/a	n/a	n/a	$52.4K	n/a
Free Cash Flow	n/a	n/a	n/a	n/a	-$24.66M	n/a	n/a	n/a	n/a	$3.04M	n/a
Share Repurchases	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$389	n/a
Shares Outstanding	47.23M	43.27M	6.99M	6.99M	5.34M	5.34M	42.72M	39.08M	38.94M	38.75M	35.02M
Weighted Average Diluted Shares	n/a	8.46M	7.57M	6.51M	5.34M	5.34M	40.92M	39.01M	n/a	n/a	n/a
EPS (Basic)	n/a	-$34.67	$0.19	-$4.61	-$6.01	-$9.35	$0.05	-$1.85	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView